Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (NCT06801834)
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology and Hematology — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (220 Sites)
Showing the first 25 of 220 sites.
- Alaska Oncology and Hematology — Anchorage, Alaska
- Genesis Cancer and Blood Institute — Hot Springs, Arkansas
- Los Angeles Cancer Network — Anaheim, California
- Boca Raton Regional — Miami, Florida
- Hope and Healing Cancer Services — Hinsdale, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
- Springfield Clinic — Springfield, Illinois
- Parkview Research Center — Fort Wayne, Indiana
- IU Health Ball Memorial Hospital and Physicians - Cancer Center - Muncie — Muncie, Indiana
- Northwest Cancer Centers — Dyer, Kentucky
- St. Claire Regional Medical Ce — Morehead, Kentucky
- Owensboro Health Mitchell Memorial Cancer Center — Owensboro, Kentucky
- MaineHealth Cancer Care — Scarborough, Maine
- OptumCare Cancer Care — Las Vegas, Nevada
- New Mexico Oncology Hematology Consultants, Ltd — Albuquerque, New Mexico
- University Hospitals Seidman Cancer Center — Sandusky, Ohio
- Taylor Cancer Research Foundation — Toledo, Ohio
- Spoknwrd Clinical Trials Inc. — Easton, Pennsylvania
- Hendrick Health System — Abilene, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — New Braunfels, Texas
- The University of Texas Health Science Center at Tyler — Tyler, Texas
- Gundersen Health System — West Salem, Wisconsin
- Hospital Britanico de Buenos Aires — Buenos Aires,
- Universidad de Buenos Aires - Facultad de Medicina - Instituto Alexander Fleming (Buenos Aires) — Buenos Aires,
📞 Contact the Study Coordinator
Phone: 1-833-445-3230 (GILEAD-0)
Email: GileadClinicalTrials@gilead.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Iadademstat + SBRT With Atezo in ES-SCLC — New Haven, Connecticut
Explore by condition: All Extensive Stage Small Cell Lung Cancer (ES-SCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.